The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | SEER-based analysis: higher second primary malignancy risk in Hispanic and API DLBCL survivors
Pallawi Torka, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses findings from a SEER-based analysis showing a higher risk of second primary malignancies among Asian/Pacific Islander (API) and Hispanic survivors of diffuse large B-cell lymphoma (DLBCL). Dr Torka highlights that these findings are exploratory and may impact follow-up of DLBCL survivors. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
